Recombinant DLL3 (Rovalpituzumab Biosimilar) 抗体
-
- 抗原 See all DLL3 (Rovalpituzumab Biosimilar) products
- DLL3 (Rovalpituzumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Human
- Expression System
- CHO Cells
-
克隆类型
- 单克隆
-
标记
- This DLL3 (Rovalpituzumab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
- 原理
- Anti-DLL3 Reference Antibody (rovalpituzumab)
- 序列
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW INTYTGEPTY ADDFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARIG DSSPSDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG,EIVMTQSPAT LSVSPGERAT LSCKASQSVS NDVVWYQQKP GQAPRLLIYY ASNRYTGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ DYTSPWTFGQ GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
- 产品特性
- Anti-DLL3 Reference Antibody (rovalpituzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
- 纯度
- >95 %
- 亚型
- IgG1
-
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 说明
-
Therapeutic Agents by Target and Mechanism: DLL3 inhibitors
Conditions: Cancer Lung Cancer (advanced small cell)
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 浓度
- 1 mg/mL
- 缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- 储存条件
- 4 °C,-80 °C
- 储存方法
- +4°C,-80°C
-
- 抗原
- DLL3 (Rovalpituzumab Biosimilar)
- Abstract
- DLL3 (Rovalpituzumab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
- Synonyms: Delta Like Canonical Notch Ligand 3, D3
- 分子量
- 145.5 kDa
- UniProt
- Q9NYJ7
-